Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 9/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.40 |
| ▸ | L3MBTL4 | Q8NA19 | 2/20 | 0.40 |
| ▸ | MBTD1 | Q05BQ5 | 3/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9989911 | 0.85 | TP53 (0.34) | L3MBTL3L3MBTL1L3MBTL4MBTD1KDM5A | |
| SCHEMBL17634304 | 0.83 | JAK2 (0.41) | L3MBTL3L3MBTL1L3MBTL4MBTD1 | |
| SCHEMBL21245631 | 0.82 | SMN1; SMN2 (0.41) | L3MBTL3L3MBTL1L3MBTL4MBTD1KDM5A | |
| SCHEMBL119040 | 0.82 | AOC3 (0.37) | L3MBTL1HSD11B1ALDH1A1 | |
| SCHEMBL30032998 | 0.82 | GAA (0.53) | TP53FAAHALDH1A1 | |
| SCHEMBL29099876 | 0.81 | JAK1 (0.43) | L3MBTL3L3MBTL1L3MBTL4MBTD1ALDH1A1 | |
| SCHEMBL16670233 | 0.80 | FPR2 (0.48) | TP53ALDH1A1MAPTTHRB | |
| SCHEMBL29099878 | 0.80 | HTR1A (0.37) | L3MBTL3L3MBTL1MBTD1ALDH1A1 | |
| SCHEMBL30031731 | 0.79 | SMN1; SMN2 (0.56) | — | |
| SCHEMBL31482726 | 0.79 | AOC3 (0.36) | L3MBTL1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
| CN-116693518-A | Synthesis and application of EGFR inhibitor | 江南大学 | 2023-09-05 | — | — | CN | disclosed |
| EP-3197870-B1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2020-08-19 | — | — | EP | disclosed |
| EP-3063139-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-11-21 | — | — | EP | disclosed |
| US-20180141927-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-05-24 | — | — | US | disclosed |
| US-9862701-B2 | Inhibitors of KRAS G12C mutant proteins | ARAXES PHARMA LLC (US) | 2018-01-09 | — | — | US | disclosed |
| EP-3197870-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | Araxes Pharma LLC (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3063139-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-09-07 | — | — | EP | disclosed |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2016-04-21 | — | — | US | disclosed |
| WO-2016049524-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| US-9120777-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-01 | — | — | US | disclosed |
| WO-2015064083-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | WO | disclosed |
| US-20150119412-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | L3MBTL3 806/4885L3MBTL1 328/4885L3MBTL4 1061/4885 |
| US-20150119412-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR4, SSTR2 | L3MBTL3 4875/4885L3MBTL1 4878/4885L3MBTL4 4870/4885 |
| US-20180141927-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | L3MBTL3 806/4885L3MBTL1 328/4885L3MBTL4 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.